Assessment of the First and Second Generation Antihistamines Brain Penetration and Role of P-Glycoprotein
- 789 Downloads
The sedating effect of first generation H1-antihistamines has been associated with their ability to penetrate the blood-brain barrier (BBB) and lack of efflux by P-glycoprotein (Pgp). Second generation H1-antihistamines are relatively free of sedation and their limited brain penetration has been suggested to arise from Pgp-mediated efflux. The objective of this work was to evaluate the role of Pgp in brain penetration of first and second generation antihistamines.
Potential of antihistamines to be Pgp substrates was tested in vitro using Madin Darby canine kidney cells transfected with human Pgp. The role of Pgp in limiting brain penetration of antihistamines was tested by using the in situ brain perfusion technique.
Majority of antihistamines were Pgp substrates in vitro. Following in situ brain perfusion, the first generation antihistamines substantially penetrated into rat brain independently from Pgp function. The second generation antihistamines terfenadine and loratadine, achieved substantial brain penetration, which was further enhanced by Pgp inhibition by cyclosporin A (CSA). In contrast, fexofenadine and cetirizine, penetrated brain poorly regardless of CSA administration.
Antihistamines greatly differ in their ability to cross the BBB as well as in the role of Pgp in limiting their transport into the CNS in vivo.
Key wordsantihistamine blood-brain barrier P-glycoprotein efflux brain perfusion
central nervous system
unidirectional transfer constant
apparent permeability coefficient
The authors are grateful to Hilltop Labs (Scottdale, PA, USA) for their assistance in this work.
- 4.A. M. ter Laak, G. J. Bijloo, M. J. E. Fisher, K. G. M. Donne-Op, P. A. Carrupt, B. Testa, and H. Timmerman. Serum protein binding of histamine H1-antagonists: a comparative study on the serum protein binding of a sedating (3H-mepyramine) and a non-sedating H1-antagonist (3H-loratadine). Eur. J. Pharm. Sci. 4:307–319 (1996).CrossRefGoogle Scholar
- 10.A. H. Schinkel, J. J. M. Smit, O. van Tellingen, J. H. Beijnen, E. Wagenaar, L. van Deemter L, C. A. A. M. Mol, M. A. van der Valk, E. C. Robanaus-Maandag, H. P. J. te Riele, A. J. M. Berns, and P. Borst. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491–502 (1994).PubMedCrossRefGoogle Scholar
- 14.J. W. Polli, T. M. Baughman, J. E. Humphreys, K. H. Jordan, A. L. Mote, J. A. Salisbury, T. K. Tippin, and C. J. Serabjit-Singh. P-glycoprotein influences the brain concentration of cetirizine (Zyrtec), a second-generation non-sedating antihistamine. J. Pharm. Sci. 92:2082–2089 (2003).PubMedCrossRefGoogle Scholar
- 16.K. M. Mahar Doan, S. A. Wring, L. J. Shampine, K. H. Jordan, J. P. Bishop, J. Kratz, E. Yang, C. J. Serabijit-Singh, K. K. Adkison, and J. W. Polli. Steady-state brain concentrations of antihistamines in rats: interplay of membrane permeability, P-glycoprotein efflux and plasma protein binding. Pharmacology 72:92–98 (2004).PubMedCrossRefGoogle Scholar
- 17.F. Bonifazi, L. Provinciali, L. Antonicelli, M. B. Bilo, S. Pucci, M. Signorino, B. Franciolino, B. Censori, P. Pagelli, and A. Iudice. Comparative study of terfenadine and cetirizine in hay fever: assessment of efficacy and central nervous system effects. J. Investig. Allergol. Clin. Immunol. 5:40–46 (1995).PubMedGoogle Scholar
- 20.M. Tashiro, Y. Sakurada, K. Iwabuchi, H. Mochizuki, M. Kato, M. Aoki, Y. Funaki, M. Itoh, R. Iwata, D. F. Wong, and K. Yanai. Central effects of fexofenadine and cetirizine; measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography. J. Clin. Pharmacol. 44:890–900 (2004).PubMedCrossRefGoogle Scholar
- 22.K. M. Mahar Doan, J. E. Humphreys, L. O. Webster, S. A. Wring, L. J. Shampine, C. J. Serabjit-Singh, K. K. Adkison, and J. W. Polli. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J. Pharmacol. Exp. Ther. 303:1029–1037 (2002).PubMedCrossRefGoogle Scholar
- 25.A. Doran, R. S. Obach, B. J. Smith, N. A. Hosea, S. Becker, E. Callegari, C. Chen, X. Chen, E. Choo, J. Cianfrogna, L. M. Cox, J. P. Gibbs, M. A. Gibbs, H. Hatch, C. E. C. A. Hop, I. N. Kasman, J. LaPerle, J. Liu, X. Liu, M. Logman, D. Maclin, F. M. Nedza, F. Nelson, E. Olson, S. Rahematpura, D. Raunig, S. Rogers, K. Schmidt, D. K. Spracklin, M. Szewc, M. Troutman, E. Tseng, M. Tu, J. W. Van Deusen, K. Venkatakrishnan, G. Walens, E. Q. Wang, D. Wong, A. S. Yasgar, and C. Zhang. The impact of P-glucoprotein on the disposition of drugs targeted for indications in the central nervous system: evaluation using MDR1A/1B knockout mouse model. Drug Metab. Dispos. 33:165–174 (2005).PubMedCrossRefGoogle Scholar
- 40.S. G. Summerfield, A. J. Stevens, L. Cutler, M. C. Osuna, B. Hammond, S. P. Tang, A. Hersey, D. Spalding, and P. Jeffrey. Improving the in vitro prediction of in vivo CNS penetration: integrating permeability, Pgp efflux and free fractions in blood and brain. J. Pharmacol. Exp. Ther. 316:1282–1290 (2006).PubMedCrossRefGoogle Scholar
- 41.X. Liu, B. J. Smith, C. Chen, E. Callegari, S. L. Backer, X. Chen, J. Cianfrogna, A. C. Doran, S. D. Doran, J. P. Gibbs, N. Hosea, J. Liu, F. R. nelson, M. A. Szewc, and J. V. Deusen. Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding. J. Pharmacol. Exp. Ther. 313:1254–1262 (2005).PubMedCrossRefGoogle Scholar